Ratner M Ia, Serov V V, Varshavskiĭ V A, Biriukova L S, Stenina I I
Ter Arkh. 1990;62(6):42-6.
In 70 patients with functionally compensated chronic glomerulonephritis (CGN), the disease outcomes were elucidated after the use of the 4-component therapy (a cytostatic, an anticoagulant, an antiaggregation agent and prednisone). The therapy appeared much more effective in the nephrotic types of CGN than in the active nephritic types. Remission was only attained in a subgroup of patients with the active types: with an early stage of the maximally active type of mesangiocapillary CGN. In the nephrotic type CGN, the therapy was effective in short-phase disease and ineffective in long persistence of that syndrome. In the nephrotic types, mesangioproliferative CGN as well as the short-phase nephrotic syndrome irrespective of the morphological type turned out predictors of a favourable outcome following the treatment. No effect can be predicted in focal segmental hyalinosis/sclerosis accompanied by arterial hypertension and the protracted nephrotic syndrome.
在70例功能代偿性慢性肾小球肾炎(CGN)患者中,采用四联疗法(一种细胞抑制剂、一种抗凝剂、一种抗聚集剂和泼尼松)后阐明了疾病结局。该疗法在肾病型CGN中似乎比在活动性肾炎型中更有效。仅在活动性类型的患者亚组中实现了缓解:即处于系膜毛细血管性CGN最大活动型的早期阶段。在肾病型CGN中,该疗法在疾病短期有效,而在该综合征长期持续时无效。在肾病型中,系膜增生性CGN以及无论形态学类型的短期肾病综合征都是治疗后预后良好的预测指标。对于伴有动脉高血压和持续性肾病综合征的局灶节段性玻璃样变/硬化,无法预测其疗效。